Cargando…

FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma

BACKGROUND: Segmental genomic copy number alterations, such as loss of 11q or 3p and gain of 17q, are well established markers of poor outcome in neuroblastoma, and have been suggested to comprise tumor suppressor genes or oncogenes, respectively. The gene forkhead box P1 (FOXP1) maps to chromosome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ackermann, Sandra, Kocak, Hayriye, Hero, Barbara, Ehemann, Volker, Kahlert, Yvonne, Oberthuer, André, Roels, Frederik, Theißen, Jessica, Odenthal, Margarete, Berthold, Frank, Fischer, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251948/ https://www.ncbi.nlm.nih.gov/pubmed/25406647 http://dx.doi.org/10.1186/1471-2407-14-840

Ejemplares similares

Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma
por: Kocak, H, et al.
Publicado: (2013)

Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma
por: Voth, Harald, et al.
Publicado: (2009)

Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment
por: Rosswog, Carolina, et al.
Publicado: (2017)

Reliable assessment of telomere maintenance mechanisms in neuroblastoma
por: Meeser, Alina, et al.
Publicado: (2022)

Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients
por: Oberthuer, A, et al.
Publicado: (2010)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
por: Berthold, Frank, et al.
Publicado: (2021)

Role of PP2Cα in cell growth, in radio- and chemosensitivity, and in tumorigenicity
por: Lammers, Twan, et al.
Publicado: (2007)

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
por: Wong, Matthew, et al.
Publicado: (2019)

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
por: Westermann, Frank, et al.
Publicado: (2008)

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes
por: Warnat, Patrick, et al.
Publicado: (2007)

A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis
por: Kreitz, Kiana, et al.
Publicado: (2019)

γ-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets
por: Dorneburg, Carmen, et al.
Publicado: (2016)

The role of complex genomic alterations in neuroblastoma risk estimation
por: Fischer, Matthias, et al.
Publicado: (2010)

Extrauterine Placental Perfusion and Oxygenation in Infants With Very Low Birth Weight: A Randomized Clinical Trial
por: Kuehne, Benjamin, et al.
Publicado: (2023)

Triptolide inhibits cell proliferation and tumorigenicity of human neuroblastoma cells
por: YAN, XIAOMIN, et al.
Publicado: (2015)

Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity
por: Yang, Chia-Lung, et al.
Publicado: (2020)

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months
por: Fischer, Janina, et al.
Publicado: (2017)

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
por: Fischer-Mertens, Janina, et al.
Publicado: (2022)

Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial
por: Berthold, Frank, et al.
Publicado: (2021)

MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity
por: Samaraweera, Leleesha, et al.
Publicado: (2014)

Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity
por: Alptekin, Ahmet, et al.
Publicado: (2019)

An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma
por: Formicola, Daniela, et al.
Publicado: (2016)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β
por: Wang, Mei, et al.
Publicado: (2015)

Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation
por: Yang, Liqun, et al.
Publicado: (2019)

Different tumorigenicity and distinct metastasis and gene signature between orthotopic and subcutaneous neuroblastoma xenografted mice
por: Han, Rui, et al.
Publicado: (2022)

Low-dose interferon-γ-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity
por: Airoldi, I, et al.
Publicado: (2004)

Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration
por: Zaatiti, Hayat, et al.
Publicado: (2018)

Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells
por: Nakata, Rie, et al.
Publicado: (2017)

Anti-Tumorigenic Effect of a Novel Derivative of 2-Hydroxyoleic Acid and the Endocannabinoid Anandamide on Neuroblastoma Cells
por: Golan, Hana, et al.
Publicado: (2022)

Overexpression of SIRT6 attenuates the tumorigenicity of hepatocellular carcinoma cells
por: Wang, Yadong, et al.
Publicado: (2017)

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2018)

Knockdown of N-Acetylglucosaminyltransferase-II Reduces Matrix Metalloproteinase 2 Activity and Suppresses Tumorigenicity in Neuroblastoma Cell Line
por: Hall, M. Kristen, et al.
Publicado: (2020)

Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2019)

Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma
por: Powers, John T, et al.
Publicado: (2016)

A Very Rare Adult Case with Neuroblastoma
por: Selcukbiricik, Fatih, et al.
Publicado: (2011)

GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes
por: Hoene, V, et al.
Publicado: (2009)

FoxP3(+) Regulatory T Cells Attenuate Experimental Necrotizing Enterocolitis
por: Dingle, Bridgette M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bhmeh3koqcop18mdhihap40loj